Here, we show that genetic and pharmacological inhibition of Apelin is a feasible strategy to reduce tumor blood vessel formation, vessel leakiness, and hypoxia, as well as to reduce suppressive immune cell infiltration, thereby significantly diminishing growth of primary lung and mammary tumors. This evidence concerns the gene APLN and breast cancer.